Septerna Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.84 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $38.05Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1.8B Enterprise Value $1.7B Shares Outstanding 45.1M diluted Moat Rating None Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Septerna, Inc. is a clinical-stage biotechnology company pioneering oral small-molecule drug discovery targeting G protein-coupled receptors (GPCRs) via its proprietary Native Complex Platform. By successfully reconstituting functional GPCRs outside of cells, Septerna bypasses historical structural biology limitations, enabling rapid screening and development of oral alternatives to large-molecule injectables. Backed by a massive $2.2 billion collaboration with Novo Nordisk in cardiometabolic diseases and a robust cash runway extending into 2029, Septerna is uniquely positioned to capture significant market share in endocrinology, immunology, and metabolic disorders. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$38.00 Mean target$53.11 High · most bullish analyst$62.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $38.00 Clinical delays in the SEP-631 Phase 2b trial or unfavorable safety/tolerability signals in the SEP-479 Phase 1 trial slow pipeline momentum. Increased R&D burn rates compress the cash runway, and a lack of near-term milestone achievements under the Novo Nordisk partnership pressures the valuation toward the lower analyst floor. Base CaseCentral scenario $53.11 Matches the consensus meanSepterna successfully initiates the Phase 2b trial for SEP-631 in Chronic Spontaneous Urticaria (CSU) in H2 2026 and reports positive Phase 1 safety and PK data for SEP-479 in late 2026 or early 2027. The company maintains its projected cash runway into 2029, supported by steady progress in its partnered metabolic programs with Novo Nordisk. Bull CaseUpside scenario $62.00 Rapid clinical validation of SEP-479 (oral PTH1R agonist) and SEP-631 (MRGPRX2 NAM) triggers early licensing options or accelerated Phase 2/3 pathways. The Novo Nordisk collaboration yields early discovery milestones, and the platform delivers a highly anticipated TSHR development candidate for Graves' disease ahead of schedule, driving the stock toward the high-end analyst target. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |